Monitor the pace of selling by PIPE investors (Bain Capital, Redmile, TCG Crossover, Nantahala) as overhang could pressure the stock near-term. The company's cash runway extended into 2029 after the PIPE and debt prepayment reduces urgency for further capital.
Drug in focus
ADCT drug pipeline →ZYNLONTA
◆ Mixed Named in this S-3- Impact
- Phase
- Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
- Time to market
- Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
- Next catalyst
- None dated
What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $1.51entry
- T+1 · 6d ago +5.96%α +4.64% · $1.60
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ADC Therapeutics filed an S-3 registration statement to register 61,000,000 common shares for resale by investors who participated in the October 2026 $86.6M PIPE. The company will not receive proceeds from share sales but may receive up to CHF 3.8M if pre-funded warrants are exercised for cash. This filing is a routine contractual obligation from the PIPE, not a new offering, and follows the company's recent debt restructuring and Q3 revenue growth.
Key Facts
- S-3 registers 61,000,000 common shares for resale by selling shareholders from the October 2026 PIPE
- Includes 12,911,347 common shares and 48,088,653 shares issuable upon exercise of pre-funded warrants
- Company will not receive proceeds from share sales; may receive up to CHF 3,847,092 if pre-funded warrants exercised for cash
- PIPE raised $86.6M at $1.42 per share and $1.324 per pre-funded warrant, closed October 22, 2026
- Filed concurrently with Q3 2026 10-Q showing net product revenue of $21.0M, up 33% YoY
- Registration is a contractual obligation under the securities purchase agreements, not a new capital raise
Financial Impact
Up to 61,000,000 shares registered for resale; potential cash proceeds to company of CHF 3,847,092 from warrant exercise
Risk Factors
- Potential near-term selling pressure as PIPE investors resell registered shares into the market
- Pre-funded warrants subject to 9.99% beneficial ownership limitations, limiting immediate exercise and share overhang
- LOTIS-5 confirmatory trial showed Grade 5 safety imbalance (13.2% vs 4.6%) flagged by FDA as benefit-risk concern
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0000950103-26-017177 |
| Document: dp256517_ex0501.htm | 0000950103-26-017177 |
| Document: dp256517_exfilingfees.htm | 0000950103-26-017177 |
| Document: dp256517_ex2301.htm | 0000950103-26-017177 |
| Document: 0000950103-26-017177-index-headers.html | 0000950103-26-017177 |
| Document: 0000950103-26-017177-index.html | 0000950103-26-017177 |
| Document: 0000950103-26-017177.txt | 0000950103-26-017177 |
Track record
14 reports on ADCT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $1.41 Now $1.25 −11.35% settles Dec 15
- Nov 9, 20267d ago S-3 Neutral 3/10 Viewing Entry $1.51 Now $1.25 −17.22% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $1.67 Now $1.25 −25.15% settles Dec 8
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $1.64 Now $1.25 −23.78% settles Dec 4
- Nov 3, 202613d ago S-4 Neutral 3/10 Entry $1.72 Now $1.25 −27.33% settles Dec 3
- Oct 29, 202618d ago SC 13G Neutral 4/10 Entry $1.53 Now $1.25 −18.30% settles Nov 30
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $1.70 to $1.51 Now $1.25 −26.47% ▼ −11.18% −7.57% vs SPY
- Aug 6, 202614w ago Press Release Neutral 1/10 Entry $1.13 to $1.32 Now $1.25 +10.62% ▲ +16.81% +16.21% vs SPY
- Jul 2, 202619w ago 8-K Neutral 2/10 Entry $1.19 to $1.11 Now $1.25 +5.04% ▼ −6.72% −6.31% vs SPY
- Jun 3, 202623w ago 8-K Mixed 6/10 Entry $1.32 to $1.19 Now $1.25 −5.30% ▼ −9.85% −8.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers